Ceribell, Inc. (CBLL) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Ceribell, Inc. (CBLL) stock forecast summary
Our AI ranks Ceribell, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Ceribell, Inc. is a small-cap company with a market capitalization of $961M. It ranks number 8 by market capitalization among the 30 Electromedical & Electrotherapeutic Apparatus issuers in our coverage with a current forecast. Its Gross Margin of 88.9% is the highest of the 27 peers that report one.
For CBLL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 237 forecast dates between 2024-11-15 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 280 forecast dates between 2024-11-15 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, CBLL included.
Follow CBLL freeCBLL price chart and AI forecast
How CBLL ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Ceribell, Inc. (CBLL) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Electromedical & Electrotherapeutic Apparatus peers listed below that report each metric.
Valuation & Market
| Metric | CBLL | Rank |
|---|---|---|
| Market Cap | $961M | 8/30 |
| P/B Ratio | 7.49x | 4/23 |
| EPS | $-1.59 | – |
| Book Value/Share | $3.34 | – |
| Revenue/Share | $2.66 | – |
| FCF/Share | $-1.43 | – |
Profitability & Margins
| Metric | CBLL | Rank |
|---|---|---|
| ROE | -51.4% | 12/19 |
| ROA | -39.7% | 15/24 |
| ROIC | -46.9% | 19/23 |
| Gross Margin | 88.9% | 1/27 |
| Operating Margin | -68.6% | 20/28 |
| Net Margin | -64.7% | 17/22 |
| EBT Margin | -64.7% | 19/28 |
Financial Health
| Metric | CBLL | Rank |
|---|---|---|
| Current Ratio | 9.18x | 3/30 |
| Quick Ratio | 8.79x | 2/29 |
| D/E Ratio | 0.30x | 19/25 |
| Financial Leverage | 1.30x | 20/25 |
| Interest Coverage | -45.4x | 19/30 |
| Working Capital | $141M | 9/29 |
Cash Flow
| Metric | CBLL | Rank |
|---|---|---|
| Operating Cash Flow | -$54M | 30/30 |
| Free Cash Flow | -$55M | 14/14 |
| Capital Spending | -$690K | 7/14 |
| FCF/Sales | -53.7% | 11/14 |
| CapEx/Sales | 0.7% | 11/14 |
Operational Efficiency
| Metric | CBLL | Rank |
|---|---|---|
| Asset Turnover | 0.61x | 9/19 |
| Receivables Turnover | 6.4x | 10/20 |
| Inventory Turnover | 1.7x | 17/27 |
| Fixed Assets Turnover | 57.9x | 5/20 |
| Days Sales Outstanding | 57 days | 11/20 |
| Days Inventory | 217 days | 11/27 |
| Payables Period | 103 days | 10/24 |
| Cash Conversion Cycle | 172 days | 6/19 |
Income Statement
| Metric | CBLL | Rank |
|---|---|---|
| Total Revenue | $102M | 8/19 |
| Operating Income | -$70M | 30/30 |
| Net Income | -$66M | 23/24 |
| R&D Expense | $23M | 8/28 |
| SG&A Expense | $172M | 8/26 |
| Cost of Goods Sold | $11M | 16/27 |
Dividend & Shareholder Information
| Metric | CBLL | Rank |
|---|---|---|
| Shares Outstanding | 38M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $158M | 94.9% of assets |
| Cash & Short-term Investments | $33M | 19.6% of assets |
| Accounts Receivable | $16M | 9.6% of assets |
| Inventory | $7M | 4.1% of assets |
| Total Liabilities | $38M | 22.9% of assets |
| Short-term Debt | $14M | 8.4% of assets |
CBLL quarterly financials and insider trading
Ceribell, Inc. (CBLL) industry peers
Companies classified under the same SEC industry code as Ceribell, Inc. (Electromedical & Electrotherapeutic Apparatus): 32 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| CBLL Ceribell, Inc. | ▲ | $961M |
| MDT Medtronic Plc | ▼ | $121.20B |
| ITGR Integer Holdings Corp | ▼ | $4.31B |
| LIVN Livanova Plc | ▼ | $4.27B |
| TMDX Transmedics Group, Inc. | ▲ | $2.45B |
| BLFS Biolife Solutions Inc | ▶ | $1.89B |
| AXGN Axogen, Inc. | ▲ | $1.86B |
| CNMD Conmed Corp | ▼ | $1.40B |
| INMD Inmode Ltd. | ▼ | $814M |
| CV Capsovision, Inc | ▶ | $323M |
| ELMD Electromed, Inc. | ▼ | $229M |
| FOCL Edap Tms Sa | ▲ | $153M |
| VANI Vivani Medical, Inc. | ▶ | $104M |
| STXS Stereotaxis, Inc. | ▶ | $101M |
| NRXS Neuraxis, Inc | ▲ | $97M |
| HYPR Hyperfine, Inc. | ▲ | $77M |
| OM Outset Medical, Inc. | ▲ | $77M |
| ECOR Electrocore, Inc. | ▲ | $71M |
| POSC Positron Corp | ▲ | $53M |
| VASO Vaso Corp | ▲ | $51M |
| POCI Precision Optics Corporation, Inc. | ▲ | $48M |
| QTI Qt Imaging Holdings, Inc. | ▶ | $35M |
| ITOC Itonic Holdings Ltd | ▼ | $29M |
| GTHP Guided Therapeutics Inc | ▲ | $18M |
| IRIX Iridex Corp | ▲ | $14M |
| NDRA Endra Life Sciences Inc. | ▶ | $7M |
| ADMT Adm Tronics Unlimited, Inc. | ▶ | $3M |
| NXL Nexalin Technology, Inc. | ▼ | $2M |
| NUWE Nuwellis, Inc. | ▼ | $2M |
| ESMC Escalon Medical Corp | ▲ | $1M |
| HCIL Hongchang International Co., Ltd | ▼ | N/A |
| YBGJ Yubo International Biotech Ltd | ▶ | N/A |
Where CBLL sits on the market map
Ceribell, Inc. (CBLL) stock news
Loading...
Ceribell, Inc. (CBLL) stock forecast FAQ
What is the Ceribell, Inc. (CBLL) stock forecast?
Our AI ranks Ceribell, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Ceribell, Inc. stock predictions?
For CBLL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 44.0%, measured on 237 forecast dates between 2024-11-15 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 30.0%, measured on 280 forecast dates between 2024-11-15 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Ceribell, Inc. forecasts updated?
Ceribell, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Ceribell, Inc.'s industry peers?
32 issuers in our coverage, CBLL included, share the SEC industry code Electromedical & Electrotherapeutic Apparatus. The largest are: Medtronic Plc (MDT), Integer Holdings Corp (ITGR), Livanova Plc (LIVN), Transmedics Group, Inc. (TMDX), Biolife Solutions Inc (BLFS), Axogen, Inc. (AXGN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.